Physician profile
Stanley Adkins
NPI 1972609493
$7,344.81
in general payments reported to CMS, 2019-2025
37 companies · $92.35 in 2025
The $92.35 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,527 · 2020: $1,536 · 2021: $1,830 · 2022: $1,295 · 2023: $1,010 · 2024: $55.01 · 2025: $92.35.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,157.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,157.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,130.32 | 2019-2023 | Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $611.95 | 2019-2023 | Jardiance |
| Amgen INC. | $598.49 | 2019-2025 | Repatha, Repatha, Otezla |
| Amarin Pharma, INC. | $545.39 | 2019-2023 | |
| Antares Pharma, INC. | $532.24 | 2022-2023 | Xyosted, Tlando, Nocdurna |
| Abbvie INC. | $521.30 | 2019-2023 | Creon, Linzess, Ubrelvy |
| Glaxosmithkline, LLC. | $442.16 | 2019-2023 | Trelegy Ellipta |
| Lilly USA, LLC | $426.89 | 2019-2023 | Jardiance, Emgality, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $371.32 | 2019-2023 | Farxiga |
| Allergan, INC. | $295.68 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $277.11 | 2019-2022 | |
| Paratek Pharmaceuticals, INC. | $197.72 | 2022-2023 | Nuzyra |
| Kowa Pharmaceuticals America, INC. | $174.08 | 2020-2023 | Livalo, Seglentis |
| Janssen Pharmaceuticals, INC | $145.67 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $139.94 | 2019-2021 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $136.48 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $102.42 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $80.95 | 2019-2020 | |
| Pfizer INC. | $71.56 | 2019-2021 | |
| Biogen, INC. | $69.73 | 2020-2022 | |
| Clarus Therapeutics INC. | $66.44 | 2021 | |
| Tactile Systems Technology INC | $47.25 | 2020 | |
| Esperion Therapeutics, INC. | $42.22 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $35.51 | 2021 | |
| Sanofi-Aventis U.S. LLC | $34.81 | 2020-2021 | |
| Ironwood Pharmaceuticals, INC | $32.06 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $29.57 | 2022 | |
| Eisai INC. | $26.52 | 2021 | |
| Alfasigma USA, INC. | $24.85 | 2021 | |
| Janssen Biotech, INC. | $23.80 | 2019 | |
| Jazz Pharmaceuticals INC. | $22.44 | 2019 | |
| Shield Therapeutics INC | $19.95 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $15.73 | 2021 | |
| Daiichi Sankyo INC. | $14.50 | 2019 | |
| Impulse Dynamics (USA) INC. | $13.71 | 2022 | |
| Horizon Therapeutics Plc | $12.84 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $11.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stanley Adkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.